Goldman Sachs
XFOR icon

Goldman Sachs’s X4 Pharmaceuticals XFOR Stock Holding History

Goldman Sachs’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.64M Buy
882,134
+50,244
+6% +$188K ﹤0.01% 3999
2025
Q4 		$3.33M Buy
+831,890
New +$3.02M ﹤0.01% 4129
2025
Q3 		– Sell
-18,864
Closed -$35.8K – 6684
2025
Q2 		$35.8K Buy
18,864
+9,735
+107% +$39.8K ﹤0.01% 5944
2025
Q1 		$64.7K Sell
9,129
-6,792
-43% -$93.5K ﹤0.01% 5850
2024
Q4 		$350K Buy
15,921
+6,168
+63% +$98.3K ﹤0.01% 5428
2024
Q3 		$196K Buy
9,753
+4,047
+71% +$84.5K ﹤0.01% 5466
2024
Q2 		$99.3K Sell
5,706
-29,592
-84% -$968K ﹤0.01% 5404
2024
Q1 		$1.47M Buy
35,298
+32,872
+1,355% +$915K ﹤0.01% 4075
2023
Q4 		$61K Buy
2,426
+773
+47% +$18.8K ﹤0.01% 5356
2023
Q3 		$54.1K Sell
1,653
-9,495
-85% -$414K ﹤0.01% 5271
2023
Q2 		$649K Buy
11,148
+8,365
+301% +$430K ﹤0.01% 4598
2023
Q1 		$72.6K Buy
2,783
+950
+52% +$27.9K ﹤0.01% 5498
2022
Q4 		$54.6K Sell
1,833
-13
-0.7% -$616 ﹤0.01% 5584
2022
Q3 		$95K Buy
+1,846
New +$63.8K ﹤0.01% 5698
2022
Q1 		– Sell
-698
Closed -$48K – 6941
2021
Q4 		$48K Buy
698
+349
+100% +$44.1K ﹤0.01% 6275
2021
Q3 		$55K Sell
349
-1,451
-81% -$239K ﹤0.01% 6028
2021
Q2 		$351K Sell
1,800
-968
-35% -$243K ﹤0.01% 5430
2021
Q1 		$715K Buy
2,768
+901
+48% +$237K ﹤0.01% 4862
2020
Q4 		$360K Buy
1,867
+153
+9% +$30.1K ﹤0.01% 4796
2020
Q3 		$348K Buy
1,714
+661
+63% +$158K ﹤0.01% 4660
2020
Q2 		$294K Buy
1,053
+581
+123% +$159K ﹤0.01% 4638
2020
Q1 		$142K Sell
472
-166
-26% -$47.1K ﹤0.01% 4842
2019
Q4 		$205K Buy
638
+143
+29% +$51.3K ﹤0.01% 4886
2019
Q3 		$189K Sell
495
-573
-54% -$227K ﹤0.01% 4839
2019
Q2 		$480K Buy
+1,068
New +$543K ﹤0.01% 4419
2019
Q1 		– Sell
-130
Closed -$54K – 5494
2018
Q4 		$54K Buy
+130
New +$49.6K ﹤0.01% 5085

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Goldman Sachs's XFOR Position: Q1 2026 in Review

Goldman Sachs increased its X4 Pharmaceuticals (XFOR) stake by 6% in Q1 2026, buying an estimated $188K and bringing the position to 882,134 shares worth $3.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3999.

Goldman Sachs first reported a position in XFOR in Q4 2018 and has held it in 26 quarters since. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Goldman Sachs held 882,134 shares of X4 Pharmaceuticals worth $3.64M as of Q1 2026.
  • Goldman Sachs bought 50,244 X4 Pharmaceuticals shares in Q1 2026, an estimated $188K.
  • X4 Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3999 holding.
  • Goldman Sachs first reported a position in X4 Pharmaceuticals in Q4 2018 and has held it in 26 quarters since.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.